Exenatide Research Dosage: Published Protocol Reference
Exenatide dosage references vary by route and study context. The database lists Subcutaneous injection: 5-10 mcg, Twice daily (Byetta) and Subcutaneous injection: 2 mg, Once weekly (Bydureon). These are research-context references, not a universal protocol.
Direct Answer
Exenatide (Byetta/Bydureon) is FDA-approved for type 2 diabetes with extensive clinical data across hundreds of RCTs and real-world use. As the first GLP-1 receptor agonist approved for clinical use, it established the entire drug class. Compared to newer once-weekly GLP-1 agents like semaglutide, it has less weight-loss efficacy and inferior convenience, but its safety record spans two decades. For GLP-1 receptor agonist research, it is a reliable reference compound.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Weight Loss & Metabolic
- Best for
- Type 2 diabetes glycemic control, GLP-1 pharmacology reference compound, cardiovascular risk reduction
Research Dosage References
- <strong>Subcutaneous injection</strong> - 5-10 mcg - Twice daily (Byetta) - Start at 5 mcg twice daily for 1 month, then increase to 10 mcg twice daily. Inject within 60 minutes before morning and evening meals.
- <strong>Subcutaneous injection</strong> - 2 mg - Once weekly (Bydureon) - Extended-release microsphere formulation. Can be administered at any time of day with or without meals. Requires reconstitution.
Half-Life
2.4 hours (immediate release); steady-state over 6-7 weeks (extended release).
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Exenatide, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Boxed warning: Risk of thyroid C-cell tumors in rodents - clinical relevance in humans unknown
- Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2
- Risk of acute pancreatitis - discontinue if suspected
- Not recommended for patients with severe renal impairment (CrCl < 30 mL/min)
- Not a substitute for insulin in type 1 diabetes
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Glycemic Control (HbA1c Reduction) (Level A), Body Weight Reduction (Level A), and Cardiovascular Outcomes (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Exenatide Research Dosage: Published Protocol Reference." Last reviewed 2026-04-04. https://examinepeptides.com/answers/exenatide-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.